Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
Rev Neurol (Paris). 2018 Mar 29;:
Authors: Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N, NOMADMUS group, under the aegis of OFSEP, SFSEP
Abstract
There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a first-line therapy or as a rescue therapy. Nevertheless, considerable heterogeneity still exists concerning the pre-treatment work-up, the vaccinations required before and under treatment, the number and dosage of infusions, prevention of the risk of infusion-related reactions, prevention of infections under treatment, and frequency of therapeutic cycles. Thanks to a collaborative work among NMO-SD experts belonging to the NOMADMUS project, we provide here recommendations for all these topics concerning RTX use in NMO-SD.
PMID: 29606320 [PubMed - as supplied by publisher]

Source: Revue Neurologique - April 4, 2018 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research